8-Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease

Proteomics

Volumn 7, Issue 20, 2007, Pages 3651-3660

  Choe, Leila ^a   D'Ascenzo, Mark ^a   Relkin, Norman R ^b   Pappin, Darryl ^c   Ross, Philip ^c   Williamson, Brian ^c   Guertin, Steven ^c   Pribil, Patrick ^d   Lee, Kelvin H ^a,e  

^a Cornell University   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Applied Biosystems Framingham   (United States)

^d MDS SCIEX   (Canada)

^e UNIVERSITY OF DELAWARE   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Immunotherapy; iTRAQ; Shotgun proteomics

Indexed keywords

IMMUNOGLOBULIN; REAGENT;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CARBONIC ANHYDRASES; CEREBROSPINAL FLUID PROTEINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INDICATORS AND REAGENTS; INFUSIONS, INTRAVENOUS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PROTEOMICS;

EID: 35648942133     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700316     Document Type: Article

References (18)

1. Tonge, R., Shaw, J., Middleton, B., Rowlinson, R. et al., Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001, 1, 377-396.
2. Choe, L. H., Lee, K. H., Quantitative and qualitative measure of intralaboratory two-dimensional protein gel reproducibility and the effects of sample preparation, sample load, and image analysis. Electrophoresis 2003, 24, 3500-3507.
3. Lee, K. H., Proteomics: A technology-driven and technology-limited discovery science. Trends Biotechnol. 2001, 19, 217-222.
4. McDonald, W. H., Yates, J. R., Shotgun proteomics: Integrating technologies to answer biological questions. Curr. Opin. Mol. Ther. 2003, 5, 302-309.
5. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
6. Dodel, R. C., Du, Y., Depboylu, C., Hampel, H. et al., Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psych. 2004, 75, 1472-1474.
7. Schenk, D., Barbour, R., Dunn, W., Gordon, G. et al., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400, 173-177.
8. Weksler, M. E., Relkin, N., Turkenich, R., LaRusse, S. et al., Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002, 37, 943-948.
9. Aggarwal, K., Choe, L. H., Lee, K. H., Quantitative analysis of protein expression using amine-specific isobaric tags in Escherichia coli cells expressing rhsA elements. Proteomics 2005, 5, 2297-2308.
10. Huttlin, E. L., Hegemen, A. D., Harms, A. C., Sussman, M. R., Prediction of error associated with false-positive rate determination for peptide identification in large-scale proteomics experiments using a combined reverse and forward peptide sequence database strategy. J. Proteome Res. 2007, 6, 392-398.
11. Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A. et al., Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 2006, 28, 155-163.
12. Blacker, D., Wilcox, M. A., Laird, N. M., Rodes, L. et al., Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 1998, 19, 357-360.
13. Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N. et al., Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 118, 140-146.
14. Eder, U., Leitner, B., Kirchmair, R., Pohl, P. et al., Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J. Neural Transm. 1998, 105, 39-51.
15. Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. et al., Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 2007, 61, 120-129.
16. Nesvizhskii, A. I., Aebersold, R., Interpretation of shotgun proteomic data: The protein inference problem. Mol. Cell. Proteomics 2005, 4, 1419-1440.
17. Fishman, R. A., Cerebrospinal Fluid in Diseases of the Nervous System, 2nd edn., W. B. Saunders Company, Philadelphia 1992.
18. Nilselid, A. M., Davidsson, P., Nagga, K., Andreasen, N. et al., Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem. Int. 2006, 48, 718-728.